The renin-angiotensin system antagonism in the treatment of hypertension

被引：1

作者：

Bisognano J.D. ^{[1
]}

Cody R.J. ^{[1
]}

机构：

[1] Divisions of Hypertension and Cardiology, University of Michigan Medical Center, 3918 Taubman Center, Ann Arbor, MI 48109

来源：

Current Hypertension Reports | 1999年 / 1卷 / 4期

关键词：

Angiotensin; Renin; Candesartan; Telmisartan; Irbesartan;

D O I：

10.1007/s11906-999-0033-6

中图分类号：

学科分类号：

摘要：

The effective treatment of hypertension is associated with improved mortality and morbidity from diseases such as stroke, congestive heart failure, and renal failure. Use of medications that target the renin-angiotensin system for the treatment of hypertension can often achieve the desired decrease in blood pressure while causing a minimum of unwanted side effects. In this paper, the principles of the renin-angiotensin system antagonism are described. The approach to using these medications is discussed with special attention to specific indications as well as common side effects. Copyright © 1999 by Current Science Inc.

引用

页码：275 / 277

页数：2

共 13 条

[1]

Bertel O., Buhler F., Kiowski W., Decreased beta-adrenoreceptor responsiveness as related to age, blood pressure, and plasma catecholamines in patients with essential hypertension, Hypertension, 2, pp. 130-138, (1980)

[2]

Goldberg J., Flowerdew G., Smith E., Et al., Factors associated with age-related macular degeneration: An analysis of data from the first national Health and Nutrition Examination Survey, Am J Epidemiol, 128, pp. 700-710, (1980)

[3]

Bisognano J., Weder A., Recognition and treatment of hypertensive heart disease in the older person, Clin Geriatr, 5, pp. 33-50, (1997)

[4]

Sixth report of the joint national commission on prevention, detection and treatment of high blood pressure, Arch Intern Med, 157, pp. 2413-2446, (1997)

[5]

Gavras H., Angiotensin-converting enzyme inhibition and its impact on cardiovascular disease, Circulation, 81, pp. 381-388, (1990)

[6]

Zimmerman B., Raich P.C., Vavrek R., Stewart J., Bradykinin contribution to renal blood flow effect of angiotensinconverting enzyme inhibitor in the conscious sodium restricted dog, Circ Res, 66, pp. 234-240, (1990)

[7]

Bisognano J., Horwitz L., Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist for severe, refractory essential hypertension, West J Med, 168, pp. 272-274, (1998)

[8]

Boulet L., Milot J., Lampron N., Lacourciere Y., Pulmonary function and airway responsiveness during long-term therapy with captopril, JAMA, 261, pp. 413-416, (1989)

[9]

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, N Engl J Med, 35, pp. 293-302, (1991)

[10]

Dunn F., Oigman W., Ventura H., Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension, Am J Cardiol, 53, pp. 105-108, (1984)

← 1 2 →